Table 4.
Clinical trials for novel vaccines based on the NP against human NSVs in Phases 1–3 listed by the FDA (https://www.clinicaltrials.gov, accessed on 1 February 2022) or EMA (https://www.clinicaltrialsregister.eu, accessed on 3 February 2022) by 1 February 2022.
| Medical Condition | Clinical Trial Identifier (Regulatory Agency) | Vaccine Type | Phase (Status) | Sponsor |
|---|---|---|---|---|
| influenza | 2009-010334-21 (EMA) |
MVA * encoding NP and M1 proteins (MVA-NP + M1) |
IIa (completed in 2010) | University of Oxford |
|
NCT00993083 (FDA) |
II (completed in 2010) | |||
|
NCT01818362 (FDA) |
chimpanzee adenovirus AdOx1 encoding NP and M1 (ChAdOx1 NP + M1) | I (completed in 2015) | ||
| 2017-001103-77 (EMA) |
seasonal inactivated influenza vaccine in combination with MVA-NP + M1 |
IIb (completed in 2018) | Vaccitech Limited | |
|
NCT03300362 (FDA) |
IIb (completed in 2018) | |||
| 2021-002535-39 (EMA) |
oligomerization domain OVX313 fused to NP which formed the NP heptamer (OVX836) | IIb (ongoing) | Osivax S.A.S | |
|
NCT03594890 (FDA) |
I (completed in 2019) | |||
| RSV | 2017-004582-27 (EMA) |
MVA * encoding RSV antigens F, G (of subtypes A and B), NP and M2 (MVA-BN-RSV) |
IIa (completed in 2019) | Bavarian Nordic |
|
NCT04752644 (FDA) |
II (ongoing) | |||
| 2018-000431-27 (EMA) |
chimpanzee adenovirus Ad155 encoding F, NP and M2 proteins (ChAd155-RSV) |
I/II (completed in 2021) | GlaxoSmithKline Biologicals | |
|
NCT02491463 (FDA) |
I (completed in 2017) | |||
|
NCT03213405 (FDA) |
BCG ** encoding RSV NP (rBCG-N-hRSV) |
I (completed in 2018) | UC Chile | |
| Ebola | NCT04152486 | MVA * encoding glycoproteins of Zaire ebolavirus, Sudan ebolavirus and Marburg Marburgvirus, and NP of Taï Forest ebolavirus (MVA-BN-Filo) | III (ongoing) | London School of Hygiene and Tropical Medicine |
* MVA—modified vaccinia virus Ankara strain; ** BCG—Bacillus Calmette–Guérin.